Skip to content

Ionis Pharmaceuticals IONS Available for sale investments

Available for sale investments at other companies

BridgeBio Pharma logo
BridgeBio PharmaBBIO
Exelixis logo
ExelixisEXEL
Amgen logo
AmgenAMGN
Merck & Co. logo
Merck & Co.MRK

Other financials

Income statement

See full
Revenue$246.1M+87.0%
Gross profit$243.1M+86.8%
Operating income-$117.4M+20.0%
Net income-$92.5M+37.0%
EPS (diluted)-$0.56+39.8%

Balance sheet

See full
Cash & equivalents$173.4M-34.4%
Total debt$691.7M+334%
Total equity$491.4M+3.3%
Total assets$3.4B+22.6%

Cash flow

See full
Operating cash flow-$792.8M-426%
CapEx$21.8M+73.0%
Free cash flow-$814.6M-399%

Valuation

See full
Market cap$12.25B+159%
Enterprise value$12.77B+175%
P/S11.6×+5.0×

Profitability

See full
Gross margin98.4%-0.2pp
Operating margin-33.3%-11.0pp
Net margin-30.9%-10.5pp
FCF margin-77.4%+35.3pp

Returns & leverage

See full
Return on equity-67.6%-20.3pp
Debt / equity1.4×+1.1×
Current ratio4.1×-5.6×

Where this comes from

Reported directly by Ionis Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:AvailableForSaleSecuritiesDebtSecurities.

The official record: Ionis Pharmaceuticals’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →

Ask your AI about Ionis Pharmaceuticals's available for sale investments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Ionis Pharmaceuticals's available for sale investments?
Ionis Pharmaceuticals (IONS) reported available for sale investments of $1.75B in Q1 2026.
How has Ionis Pharmaceuticals's available for sale investments changed year-over-year?
Ionis Pharmaceuticals's available for sale investments decreased by 8.7% year-over-year, from $1.91B to $1.75B.
What is the long-term trend for Ionis Pharmaceuticals's available for sale investments?
Over 4 years (2021 to 2025), Ionis Pharmaceuticals's available for sale investments has grown at a 17.2% compound annual growth rate (CAGR), from $1.25B to $2.35B.